Co-Authors
This is a "connection" page, showing publications co-authored by VICENTE VALERO and THOMAS A BUCHHOLZ.
Connection Strength
0.989
-
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
Score: 0.136
-
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
Score: 0.119
-
Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6.
Score: 0.102
-
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
Score: 0.101
-
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006 Apr; 17(4):605-13.
Score: 0.068
-
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
Score: 0.050
-
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783.
Score: 0.037
-
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
Score: 0.036
-
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
Score: 0.033
-
Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417.
Score: 0.032
-
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
Score: 0.032
-
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
Score: 0.032
-
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
Score: 0.032
-
Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9.
Score: 0.026
-
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84.
Score: 0.025
-
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
Score: 0.024
-
Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 Dec; 21(12):2348-2355.
Score: 0.023
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
Score: 0.022
-
Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 01; 23(31):7827-35.
Score: 0.017
-
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
Score: 0.016
-
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003 Mar; 9(3):955-60.
Score: 0.014
-
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
Score: 0.013